title: [Implication of extended-spectrum beta-lactamase enterobacteriaceae in nosocomial infections in neonates].
abstract: OBJECTIVE
  The objective of this study was to determine the incidence of extended-spectrum beta-lactamase (ESBLS) enterobacteriaceae colonization and infection in hospitalized children.
  
  
  METHODS
  This prospective study was conducted in a neonatal intensive care unit from 2000 to 2009. We recorded all isolations of ESBLs enterobacteriaceae from clinical samples that were obtained from hospitalized children. Anorectal samples were taken at admission and every 10 days. We systematically recorded cases of confirmed infections that was caused by ESBLs enterobacteriacea.
  
  
  RESULTS
  A total of 46 ESBL(S) pathogens (E coli 58.7 %, Enterobacter cloacae 10.8 %, Klebsiella Pneumonia 19.5%, K. oxytoca 6.5 %, Citrobacter 4.5 %) were isolated during 10 years, the global incidence was 5.1 cases per 1000 admissions. Three infants developed nosocomial infections, E. coli sepsis and pneumonia and Enterobacter cloacae omphalitis. These patients were treated with carbapenem with significant clinical improvement. ESBLs enterobacteriaceae were found first in Klebsiella pneumonia and then predominantly in E. coli. Current efforts have focused on monitoring proper hand hygiene, evaluation of potential reservoirs of bacterial acquisition and transmission, cohorting and isolation of colonized infants, and fostering of effective inter- and intrahospital communication. Carbapenem seems to be safe in newborn and is recommended for the treatment of EBLSEs enterobacteriaceae infections.
authors.affiliation: Service de Réanimation et Pédiatrie Néonatales, AP-HP, Hôpital Robert Debré, 48, Boulevard Sérurier, 75019 Paris, France. valerie.biran@rdb.aphp.fr
authors.forename: V
authors.initials: V
authors.lastname: Biran
authors.forename: A
authors.initials: A
authors.lastname: Gaudin
authors.forename: P
authors.initials: P
authors.lastname: Mariani-Kurdjian
authors.forename: C
authors.initials: C
authors.lastname: Doit
authors.forename: E
authors.initials: E
authors.lastname: Bingen
authors.forename: Y
authors.initials: Y
authors.lastname: Aujard
mesh_terms: D001003:Anal Canal / Q000382:microbiology; D015780:Carbapenems / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology*; D016972:Enterobacter cloacae / Q000302:isolation & purification; D004755:Enterobacteriaceae / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007363:Intensive Care Units, Neonatal; D007711:Klebsiella pneumoniae / Q000302:isolation & purification; D010297:Paris; D011446:Prospective Studies; D012007:Rectum / Q000382:microbiology; D001618:beta-Lactamases / Q000627:therapeutic use*
chemical_list: D015780:Carbapenems; D001618:beta-Lactamases